Relay Therapeutics, Inc. (RLAY)
Stock Price:
$40.27 USD
1.99 (5.20%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
3.62B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-83.33M |
| Shares Out |
89.97M |
| EPS (ttm) |
-0.93 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$40.27 |
| Previous Close |
$38.28 |
| Change ($) |
1.99 |
| Change (%) |
5.20% |
| Day's Open |
38.35 |
| Day's Range |
38.35 - 40.79 |
| Day's Volume |
131,252 |
| 52-Week Range |
32.56 - 49.89 |
More Stats
| Market Cap |
3.62B |
| Enterprise Value |
3.33B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
89.97M |
| Float |
42.33M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.93 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.09M |
| Short Ratio |
8.72 |
| Short % of Float |
12.03% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.52 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-83.33M |
| Free Cash Flow |
n/a |
| Net Cash |
288.84M |
| Net Cash / Share |
3.21 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$49.33*
(22.50% upside)
Low
36.0
Current: $40.27
High
64.0
Target: 49.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -84.05 | -49.89 |
| Net Income | -75.31 | -48.79 |
| Shares Outstanding | 3.45 | 2.49 |
| Earnings Per Share | -21.82 | -19.63 |
| Operating Cash Flow | -66.13 | -44.14 |
| Capital Expenditures | -7.98 | -1.68 |
| Free Cash Flow | -74.12 | -45.82 |
| Cash & Equivalents | 357 | 422 |
| Total Debt | 24.83 | 0.18 |
| Net Cash / Debt | 332 | 422 |
| Assets | 393 | 429 |
| Liabilities | 35.73 | 7.42 |
| Book Value | -180 | -111 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Relay Therapeutics, Inc. |
| Country |
United States |
| Employees |
123 |
| CEO |
Sanjiv K. Patel |
Stock Information
| Ticker Symbol |
RLAY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RLAY |
| IPO Date |
July 16, 2020 |
Description
Relay Therapeutics operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.